Gene
U2AF1
U2AF1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (8), Actionable biomarkers (1), Trial mentions (27), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention U2AF1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 8 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 3 of 8,738 | 0.03% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 4 of 8,597 | 0.05% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 14 of 11,460 | 0.12% |
| 2022 | 2 of 8,285 | 0.02% | 12 of 13,598 | 0.09% |
| 2021 | 5 of 8,692 | 0.06% | 14 of 15,045 | 0.09% |
| 2020 | 3 of 7,640 | 0.04% | 5 of 14,459 | 0.03% |
| 2019 | 1 of 7,300 | 0.01% | 13 of 12,159 | 0.11% |
| 2018 | 3 of 6,927 | 0.04% | 15 of 11,854 | 0.13% |
| 2017 | 0 of 6,558 | 0.00% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Assay-provider ledger (8)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Genetron Health | Diagnostic provider | Clinical validation | 1 | September 27, 2024 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 1 | September 27, 2024 |
| ZYMO Research (Orange, CA) | Reagent supplier | Clinical validation | 1 | September 27, 2024 |
| Horizon Discovery | Reagent supplier | Clinical validationAnalytical validation | 2 | May 24, 2016 +1 undated |
| Life Technologies | Reagent supplier | Clinical validationAnalytical validation | 1 | May 24, 2016 |
Showing 5 of 8 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| U2AF1 oncogenic mutation | Flt3 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (27)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04802161 | Trial eligibility (AACT) |
| NCT05641831 | Trial eligibility (AACT) |
| NCT06802315 | Trial eligibility (AACT) |
| NCT07104799 | Trial eligibility (AACT) |
| NCT04588922 | Trial eligibility (AACT) |
Showing 5 of 27 trial mentions.
Target-disease associations (245)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Acanthamoeba keratitis | disorder of visual system | Mouse knockout (IMPC) |
| Albinism-deafness syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Aniridia - ptosis - intellectual disability - familial obesity | disorder of visual system | Mouse knockout (IMPC) |
| Appendix Goblet Cell Carcinoid | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 245 associations.
Vendor sourcing (96)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.643G>A (p.G215S) alteration is located in exon 8 (coding exon 8) of the U2AF1 gene. This alteration results from a G to A substitution at nucleotide po... | View ClinVar record SCV003657396.2 |
| Astex Pharmaceuticals | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Diagnosis of AML and MDS according to World Health Organization (WHO) classification that underwent first or second allogeneic HSCT with either peripher... | View trial NCT06297629 |
| Astex Pharmaceuticals | Trial collaborator | Mentioned in trial textTrial free-text mention | U2AF1 | View trial NCT06297629 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | Patients must have a diagnosis of recurrent, persistent, or progressive myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) according ... | View trial NCT03770429 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | U2AF1 | View trial NCT03770429 |
Showing 5 of 96 sourcing records.
Trial-cited literature (124)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. | Therapeutic advances in hematology | 2025 | 2 |
| Multipurpose RNA maturation factors dysregulate multiple mRNA processing steps simultaneously and provide new therapeutic opportunities. | RNA biology | 2025 | 1 |
| Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). | Leukemia | 2024 | 35 |
Showing 5 of 124 papers.
Protein variant mentions (1)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.S34F | 10 | 2012 to 2023 | PMID 36902450, PMID 37814121, PMID 35900726 |
Literature-extracted relations (25)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Doxycycline | Chemical | associate |
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. | 2015 |
| Myelodysplastic Syndromes | Disease | associate |
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. | 2023 |
| Leukemia, Myeloid, Acute | Disease | associate |
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. | 2020 |
| Myelodysplastic Syndromes | Disease | associate |
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. | 2020 |
| Erdheim-Chester Disease | Disease | associate |
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. | 2019 |
Showing 5 of 25 relation assertions.
Organizations publishing (182)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 13 | 2015 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 13 | 2015 to 2023 |
| Mass General Brigham | Hospital | 8 | 2015 to 2023 |
| The University of Texas System | Academic | 7 | 2013 to 2026 |
| Cleveland Clinic | Hospital | 6 | 2012 to 2023 |
Showing 5 of 182 organizations.
Where U2AF1 appears
- biological_process
- cancer or benign tumor
- disorder of visual system
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
229 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.